📊 IPHYF Key Takeaways
Is Innate Pharma SA (IPHYF) a Good Investment?
Innate Pharma SA lacks sufficient publicly available financial data for meaningful fundamental analysis, with only 1 metric available in the dataset. The absence of revenue, profitability, balance sheet, and cash flow information prevents assessment of financial health, operational performance, or sustainability.
Innate Pharma’s fundamentals remain weak: the company is still deeply unprofitable, revenue is small and highly dependent on milestone and collaboration income, and cash burn continues to materially outweigh operating inflows. Financial health improved versus the stressed 2024 balance sheet because of partner funding and tighter R&D spend, but the business still lacks durable commercial revenue and appears likely to need additional funding if losses persist beyond its stated runway.
Why Buy Innate Pharma SA Stock? IPHYF Key Strengths
- Operates in biopharmaceutical sector with potential for high-value therapeutic developments
- Listed on Nasdaq, providing access to US capital markets
- Early-stage biotech companies can generate significant shareholder value through successful pipeline advancement
- Liquidity improved during 2025, with cash/investments still substantial and management indicating runway into late 2026
- R&D spending declined year over year in the first half of 2025, showing some cost discipline
- Strategic partnerships and government funding provide external support and reduce sole reliance on equity markets
IPHYF Stock Risks: Innate Pharma SA Investment Risks
- Complete lack of financial transparency - no revenue, profitability, or cash position data available
- Cannot assess financial runway or cash burn rate, critical for biotech viability
- Absence of material insider purchases (0 Form 4 filings in 90 days) suggests no insider confidence signals
- Data freshness is none - unable to determine if company is actively reporting or facing regulatory issues
- No metrics to evaluate operational efficiency, R&D productivity, or development progress
- Persistent operating and net losses with no evidence of near-term self-funded profitability
- Revenue quality is weak because it is driven largely by collaborations, milestones, and grants rather than recurring product sales
- Balance sheet resilience is limited after prior negative equity and continued cash burn, raising future financing risk
Key Metrics to Watch
- Quarterly revenue and cash burn rate from actual SEC filings
- Pipeline stage advancement and clinical trial progression announcements
- Cash position and estimated runway to profitability or next funding milestone
- Quarterly operating cash burn and updated cash runway
- Collaboration/licensing revenue and shareholders' equity trend
Innate Pharma SA (IPHYF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IPHYF Profit Margin, ROE & Profitability Analysis
IPHYF vs Healthcare Sector: How Innate Pharma SA Compares
How Innate Pharma SA compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Innate Pharma SA Stock Overvalued? IPHYF Valuation Analysis 2026
Based on fundamental analysis, Innate Pharma SA has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Innate Pharma SA Balance Sheet: IPHYF Debt, Cash & Liquidity
IPHYF Revenue Growth, EPS Growth & YoY Performance
IPHYF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Innate Pharma SA (CIK: 0001598599)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IPHYF
What is the AI rating for IPHYF?
Innate Pharma SA (IPHYF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IPHYF's key strengths?
Claude: Operates in biopharmaceutical sector with potential for high-value therapeutic developments. Listed on Nasdaq, providing access to US capital markets. ChatGPT: Liquidity improved during 2025, with cash/investments still substantial and management indicating runway into late 2026. R&D spending declined year over year in the first half of 2025, showing some cost discipline.
What are the risks of investing in IPHYF?
Claude: Complete lack of financial transparency - no revenue, profitability, or cash position data available. Cannot assess financial runway or cash burn rate, critical for biotech viability. ChatGPT: Persistent operating and net losses with no evidence of near-term self-funded profitability. Revenue quality is weak because it is driven largely by collaborations, milestones, and grants rather than recurring product sales.
What is IPHYF's revenue and growth?
Innate Pharma SA reported revenue of N/A.
Does IPHYF pay dividends?
Innate Pharma SA does not currently pay dividends.
Where can I find IPHYF SEC filings?
Official SEC filings for Innate Pharma SA (CIK: 0001598599) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IPHYF's EPS?
Innate Pharma SA has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IPHYF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Innate Pharma SA has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IPHYF stock overvalued or undervalued?
Valuation metrics for IPHYF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IPHYF stock in 2026?
Our dual AI analysis gives Innate Pharma SA a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IPHYF's free cash flow?
Innate Pharma SA's operating cash flow is N/A, with capital expenditures of N/A.
How does IPHYF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).